Trials / Completed
CompletedNCT00072618
Phase II Study of Taxotere in Combination With Exisulind in Non-Small Cell Lung Cancer (NSCLC) Patients
A Phase I/II Multi-Center Study of Weekly Taxotere (Docetaxel) in Combination With Aptosyn (Exisulind) in Non-Small Cell Lung Cancer (NSCLC) Patients Who Have Failed a Prior Platinum-Containing Regimen
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 52 (planned)
- Sponsor
- Astellas Pharma Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if the combination of Taxotere and exisulind is an effective and safe treatment for patients with advanced NSCLC who have failed a prior platinum-containing regimen.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Exisulind |
Timeline
- Start date
- 2001-10-01
- Completion
- 2003-08-01
- First posted
- 2003-11-07
- Last updated
- 2011-10-20
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00072618. Inclusion in this directory is not an endorsement.